AI
EOLS icon

Allostery Investments’s Evolus EOLS Stock Holding History

Allostery Investments’s Portfolio EOLS Stock Details EOLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-60,000
Closed -$553K – 10
2025
Q2 		$553K Sell
60,000
-352,754
-85% -$3.61M 7.04% 5
2025
Q1 		$4.97M Sell
412,754
-18,363
-4% -$240K 7.16% 5
2024
Q4 		$4.76M Buy
+431,117
New +$6.06M 4.97% 5

Other funds holding EOLS

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Allostery Investments's EOLS Position: Q3 2025 in Review

Allostery Investments sold out of Evolus (EOLS) in Q3 2025, closing a stake of 60,000 shares — an estimated $553K sold.

Allostery Investments first reported a position in EOLS in Q4 2024 and held it in 3 quarters. The position peaked at $4.97M in Q1 2025. 160 funds tracked by Wall St. Rank hold EOLS as of Q3 2025.

  • Allostery Investments reported no remaining Evolus position as of Q3 2025 after selling out during the quarter.
  • Allostery Investments sold 60,000 Evolus shares in Q3 2025, an estimated $553K.
  • Allostery Investments first reported a position in Evolus in Q4 2024 and held it in 3 quarters.
  • Allostery Investments's Evolus position peaked at $4.97M in Q1 2025.
  • 160 funds tracked by Wall St. Rank held Evolus as of Q3 2025.

Based on Allostery Investments's 13F filing for Q3 2025.